-alkylating agents, including temozolomide, fotemustine and chlorozotocin. The possibility that our strategy for protective gene therapy may be highly agent and cell-type specific is unexpected and has possible implications for clinical trials of this approach using BCNU or related agents.
Introduction
Cytostatic anti-tumour therapies can result in both early doselimiting toxicity and late tissue injury. In the bone marrow acute toxicity frequently manifests as myelosuppression whilst chronic injury is more insidious and may result in the development of a secondary malignancy such as leukaemia. 1 Such myelotoxicity constrains the dose and frequency of drug exposure. A possible solution to this problem is to enhance the resistance of sensitive tissues to these effects. 2, 3 Current clinical strategies include supporting haemopoietic function by administration of growth factors or by supplying progenitor cells harvested from the peripheral blood (PBPC) of patients prior to therapy. 4, 5 To date, reported growth factor or PBPC support does provide clinical benefit in terms of reduced toxicity but not to a level at which substantial increases in dose intensity could be considered.
As an alternative strategy, we have been investigating the effects of the ex vivo transfer and in vivo expression of drug resistance factors in normal, early haemopoietic progenitor cells. This genetic chemoprotection approach has a number of theoretical advantages over PBPC or growth factor support. First, with every round of treatment the number of drug-resistant progenitors is anticipated to increase as untransduced cells would remain sensitive to toxicity, thereby potentially facilitating drug dose escalation above currently marrow suppressive levels (or at least facilitating maintenance of dose intensity). Second, while present studies focus on protecting the haemopoietic system, it may ultimately be possible to reduce collateral toxicity in the next dose limiting tissues such as lung or gut in order to extend the general utility of this approach. Third, it may be possible to integrate the gene-based protection strategy with novel approaches to tumour sensitisation. Finally, the appropriate choice of resistance factor may allow protection against the mutagenic effects associated with certain classes of anti-tumour agent.
There are a number of drug resistance functions that have been evaluated for their potential to enhance haemopoietic cell survival during chemotherapy. These include the efflux pump proteins (multiple drug resistance-1 and multi-drug resistance protein), 6, 7 aldehyde dehydrogenase, 8, 9 glutathione-S-transferases, 10 cytidine deaminase, 11 dihydrofolate reductase 12, 13 and O 6 -alkylguanine-DNA-alkyltransferase (ATase). 14, 15 The latter protein, which confers resistance to the biological effects of O 6 -alkylating agents comprising the chloroethylnitrosoureas (eg N,NЈ-bis(2-chloroethyl)-N-nitrosourea (BCNU); 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU); fotemustine) and related methylating agents (eg temozolomide; dimethyltriazenoimidazolecarboxamide (DTIC); streptozocin; procarbazine), has been widely studied in cells and animal systems. These investigations have shown that the expression of ATase in cells which are normally deficient for this function produced a marked increase in cellular resistance to toxicity, [16] [17] [18] [19] [20] [40] [41] [42] [43] [44] [45] or O 6 -beG-resistant mutants of hAT, [46] [47] [48] [49] [50] either in murine bone marrow or in human primary haemopoetic cells, has been shown to afford some degree of protection against O 6 -alkylating agentinduced toxicity in the bipotent granulocyte-macrophage progenitor population. These observations have stimulated interest in a clinical trial to protect bone marrow against BCNUinduced myelosuppression, even though evidence of enhanced resistance to BCNU in multipotent haemopoietic progenitors has not yet been reported. Recently, we have investigated whether expressing a mutant of hAT (hATPA/GA) 51, 52 that is essentially resistant to O 6 -beG in bone marrow of mice can protect day 12 spleen colony-forming cells (CFU-S) 53 from the toxic effects of temozolomide. The day 12 CFU-S, under certain conditions of transplantation, can exhibit long-term repopulating ability despite their relatively low self-maintenance capacity. 53, 54 Thus, while most day 12 CFU-S have only a transient reconstitution potential, 53, 54 they are nonetheless somewhat characteristic of the multipotent cells that represent the ideal target for genetic chemoprotection. These studies showed a reduction in toxicity even in the presence of O 6 -beG. 49, 50 To determine if this protection extended to chloroethylating agents we have, in the present study, exposed mice reconstituted with bone marrow virally transduced with a cDNA encoding hATPA/GA, to BCNU in the presence or absence of O 6 -beG. We observed protection of bipotent GM-CFC and polychromatic erythrocytes against BCNU toxicity and clastogenicity, respectively, but demonstrated that the CFU-S of hATPA/GA-transduced animals remained as sensitive to the toxicity of BCNU as those of control animals in the presence of O 6 -beG. The significance of these data for clinical trials of this approach are discussed.
Materials and methods

Materials
BCNU was purchased from Bristol-Myers Pharmaceuticals, Hounslow, UK. It was freshly dissolved in ethanol (25 mg/ml) and appropriately diluted in phosphate-buffered saline (PBS) for intraperitoneal (i.p.) injection into mice. O 6 -beG was a generous gift from Dr RS McElhinney and Prof B McMurry, Trinity College, Dublin, Ireland and was homogeneously suspended in corn oil using a TEFLON glass homogeniser (Scientific Laboratory Supplies, Nottingham, UK) for i.p. injection into mice. 5-Fluorouracil (5-FU; 250 mg/ml solution) was purchased from David Bull Laboratories, Warwick, UK. Recombinant human IL-6 was from Sandoz, Basle, Switzerland; recombinant murine IL-3 was from R&D Systems, Abingdon, UK; and recombinant rat stem cell factor was from Amgen, Thousand Oaks, CA, USA.
Producer cells
The LhATPA/GA vector which expresses the human hATPA/GA protein 52 (driven by Moloney murine leukemia virus long terminal repeat) was constructed by cloning the appropriate cDNA into a BamHI site in the retroviral vector pLX derived from the LN series of vectors. 55 The above mentioned vector construct and pcDNA3neo (10:1) were cotransfected into the ecotropic producer cells GP + E86 using Lipofectin (Life Technologies, Paisley, UK). G418-resistant LhATPA/GA-positive clones were cocultured with amphotropic GP + envAM12 cells for 7 days in a 'ping-pong' method to increase the viral titre. Amphotropic producer cells were then selected by culturing in the presence of 200 g/ml hygromycin for 7 days to eliminate the ecotropic producers. The viral titre of supernatant from the amphotropic cells was tested using NIH3T3 cells and this indicated a titre in excess of 5 × 10 5 infectious particles/ml.
Animal studies
B6D2F1 male donor mice (9-12 weeks old) were treated with 150 mg/kg 5-FU by intravenous injection. Two days later bone marrow cells were harvested from the femurs and cultured for 2 days at 37°C in DMEM supplemented with 20% foetal calf serum, 0.1% BSA, 2 mM glutamine, 10 ng/ml recombinant murine IL-3, 100 ng/ml recombinant rat stem cell factor and 200 U/ml recombinant human IL-6. The bone marrow cells were scraped from the culture flasks and overlayed on either GP+envAM 12 (mock), or LhATPA/GA retroviral producer cells for 2 days in the same medium with the addition of 4 g/ml polybrene. Supernatant cells were then collected, washed and used for cytospin preparation, GM-CFC colony plating in methylcellulose for PCR analysis and transplantation into 8-to 10-week-old bone marrow ablated (15.2 Gy, Cobalt 60 source for 16 h female B6D2F1 mice (5 × 10 6 cells per mouse).
To assess the gene transduction frequency among CFU-S, 10 recipient mice were transplanted with 1 × 10 6 cells each. The mice were sacrificed 12 days later and either spleens were fixed in 70% ethanol for immunocytochemical analysis or individual spleen colonies were carefully dissected out for DNA isolation and subsequent PCR analysis.
One month after transplantation groups of five mice were treated with BCNU (5 mg/kg, i.p. in 3% ethanol in PBS) either alone or 2 h after receiving a single dose of O 6 -beG (30 mg/kg, i.p. in corn oil): 24 h later the treated mice were sacrificed by cervical dislocation and femoral bone marrow cells were harvested and used for CFU-S and GM-CFC analysis as described previously. 39 The mean numbers of GM-CFC in untreated mice were 17 850 ± 2930 and 14 075 ± 3250 per femur in mock control and hATPA/GA mice, respectively. The mean numbers of CFU-S in untreated mice were 867 ± 99 and 897 ± 18 per femur in mock control and hATPA/GA mice, respectively.
PCR analysis
PCR analyses were carried out on individual GM-CFC colonies (n = 20) picked from methylcellulose and DNA isolated from 18 day 12 spleen colonies. Using the primers 5ЈATGGA-CAAGGATTGTGAAATGAAACG3Ј and 5ЈTCAGTTTCGGCC-AGCAGGCGG3Ј, a PCR product of 624 bp was amplified corresponding to the hAT cDNA. A DNA fragment of the murine, Y-chromosome-specific Sry gene was amplified using the primers 5ЈAAGCGCCCCATGAATGCATT3Ј and 5ЈTCCCAGCT-GCTTGCTGATCT3Ј to detect male (donor) cells in the female recipients based on the presence of a 105-bp PCR product. 56 
Immunocytochemistry
Cytospin preparations of transduced bone marrow cells and 3-m sections of day 12 spleen colonies were stained with a rabbit polyclonal antibody for human ATase which recognises hATPA/GA using a streptavidin biotin peroxidase complex detection system (Vector Laboratories, Peterborough, UK) in a modified procedure as previously described. 57 
Micronucleus test
Groups of five control and LhATPA/GA transduced mice were treated with a single dose of BCNU (0.75 mg/kg i.p. in 3% ethanol in PBS) either alone or 2 h after receiving a single dose of O 6 -beG (30 mg/kg i.p. in corn oil). The treated mice were sacrificed 24 h later by cervical dislocation and femoral marrow cells were flushed into foetal calf serum. Bone marrow smears were prepared from the cell pellets, fixed in methanol for 10 min and subsequently stained with acridine orange as described. 58 The slides were scored independently by two separate investigators for micronucleated polychromatic erythrocytes (MPCE) among 2000 polychromatic erythrocytes (PCE) and results expressed as MPCE/1000 PCE.
Statistical analysis
The unpaired Student's t-test was used to compare the difference between the control and experimental animals.
Results
Efficiency of transduction of primary murine bone marrow progenitors
The DNA from day 12 spleen colonies was used to determine if the haemopoiesis in the study animals was derived from the male donor marrow used for reconstitution. A PCR product derived from a murine Y-chromosome-specific sequence was demonstrated in all spleen colonies analysed confirming donor haemopoiesis. The same DNA samples were examined for the presence of the hATPA/GA cDNA and of 18 colonies analysed from the five recipient mice, nine proved positive for this sequence, indicating that about half of the reconstituted marrow arose from transduced cells. A similar transduction efficiency was calculated via PCR analysis of GM-CFC DNA isolated from the ex vivo-transduced marrow.
Immunocytochemical analysis of ATase expression in bone marrow and spleen colony cells
Cytospin preparations of in vitro-transduced total murine bone marrow were analysed for evidence of ATase expression using a highly specific polyclonal antibody raised against hAT which does not cross-react with murine ATase. Bone marrow that had been co-cultured with hATPA/GA producers clearly showed the presence of nuclear staining antigen in about 40-45% of the cells ( Figure 1A ). In comparison, bone marrow cultured with naive packaging cells showed no evidence of discrete antibody localisation, either in the nucleus or otherwise ( Figure 1B) .
The expression of ATase in the day 12 spleen colonies was also investigated and about 50% of colonies derived from mice reconstituted with hATPA/GA-transduced bone marrow ( Figure 1C ), were found to contain high levels of ATase protein. These data are consistent with the transduction frequency as determined by PCR. As expected, when detected the protein was localised mainly in the nucleus of the spleen colony cells.
In vivo toxicity of BCNU in hATPA/GA-transduced and mock-transduced bone marrow progenitors
Mice reconstituted with hATPA/GA-transduced or mock-transduced bone marrow were treated with BCNU (5 mg/kg) either alone or in combination with O 6 -beG (30 mg/kg) approximately 5 weeks post-transplant. These treatments had been previously demonstrated to result in significant toxicity to murine bone marrow. 39 The effect of in vivo drug treatment on the colony-forming ability of the treated marrows was assessed by comparison of the levels of CFU-S and GM-CFC in the hATPA/GA and mock transduced populations of mice. The GM-CFC levels in the mock-transduced animals treated with BCNU were reduced to 68% and 8% in the absence and presence of O 6 -beG, respectively (Figure 2 ). In the hATPA/GAtransduced mice, a modest protective effect against BCNU alone was seen in the GM-CFC, which was significant at the 5% level (P = 0.047) and equated to a 1.4-fold increased resistance over controls. In the presence of O 6 -beG, however, a more pronounced protective effect (3.5-fold, P = 0.001) was observed.
In the CFU-S assayed from the mock-transduced animals, toxicity was also observed and pretreatment with O 6 -beG significantly reduced CFU-S numbers from 38% (BCNU alone) to 5% of those in untreated controls ( Figure 3) . As with the GM-CFC population, expression of hATPA/GA conferred modest (1.6-fold, P = 0.034) protection to the CFU-S against BCNU alone. However, this survival advantage was lost when the animals were exposed to O 6 -beG prior to BCNU treatment (P = 0.133).
In vivo clastogenicity of BCNU in transduced and mock-transduced polychromatic erythrocytes
Five weeks post reconstitution, both hATPA/GA and mocktransduced mice were treated with a dose of BCNU or O 6 -beG plus BCNU that was known from previous studies to be highly clastogenic to mouse bone marrow polychromatic erythrocytes. 39 In the mock-transduced controls, there was a significant elevation in micronucleus frequency above that of the no treatment controls and this was further increased by pretreatment with O 6 -beG ( Figure 4) . In those animals reconstituted with hATPA/GA-transduced marrow there was a small but significant (P Ͻ 0.05) reduction in the number of micronuclei induced relative to the normal controls. The difference between the two groups, however, was more pronounced when mice were exposed to a combination of O 6 -beG and BCNU. In this case there was a 50% reduction (P Ͻ 0.001) in the micronucleus frequency in the animals reconstituted with the transduced compared with the mock-transduced marrow (again consistent with the observed transduction frequency). 
Discussion
A number of groups are currently investigating the utility of gene transfer of ATase for the protection of bone marrow from collateral toxicity during O 6 -alkylating agent chemotherapy. ATase-mediated protection of lineage-specific or bipotent -alkylating agents has been demonstrated. [40] [41] [42] [43] [44] [45] 59 Some of these studies have made use of mutant ATases, which exhibit various degrees of resistance to the tumour sensitiser O 6 -beG, [46] [47] [48] [49] [50] and have shown that haemopoietic cell protection is maintained under conditions where an otherwise resistant tumour might be expected to be sensitised to treatment. Despite the fact that this strategy is often referred to as stem cell protection, little direct qualitative evaluation of any protective effects that may occur in primitive haemopoietic cells has been undertaken. This is of particular importance if the strategy is to provide long-term protection against toxicity or against mutagenic, clastogenic and carcinogenic effects.
To address this issue we have made use of the multipotent day 12 CFU-S population as a surrogate marker of primitive cells in mouse bone marrow. 53 We have previously shown significant in vivo protection of day 12 CFU-S against the toxic effects of the methylating agent temozolomide, in combination with O 6 -beG, following reconstitution of mice with bone marrow which had been induced to express hATPA/GA as a result of retroviral gene transfer. 49 In the present study, we have investigated the ability of hATPA/GA expression to provide protection against BCNU, which has been used in a number of preclinical studies by other workers and is a potential agent for use in a clinical trial of ATase-mediated myeloprotection.
Following gene transfer, transduction frequencies of around 50% were seen in bone marrow GM-CFC and spleen colonies, and this correlated well with the frequency of ATase-positive cells/colonies detected by immunocytochemical analysis of bone marrow and spleen colonies derived from reconstituted mice. When the in vivo sensitivity of mock-transduced and hATPA/GA-transduced bone marrow to the cytotoxic effects of BCNU was tested, significant protection of the GM-CFC compartment was seen both in the absence and presence of O 6 -beG. The size of the protective effect in committed progenitors (1.4-to 3.5-fold) was similar to that previously reported by others following transduction of bone marrow with wild-type or single mutant forms of hAT. 40, 42, 43, 46, 59 Given this effect and from our experience with temozolomide and mitozolomide, 49, 50 we expected to see a similar protective effect in the more primitive day 12 CFU-S compartment. However, whilst a significant effect on survival was seen in the absence of O -beGresistant protection of the GM-CFC and CFU-S compartments is not obvious. Clearly, transduction of CFU-S was achieved in the original bone marrow cultures, and expression of hATPA/GA was detected in day 12 spleen colonies following reconstitution of mice. Furthermore the protection observed in the granulocyte/macrophage and erythroid lineages, 5 weeks after transplantation clearly demonstrates transduction of, and expression in, the progeny of primitive haemopoietic progenitors. One possible explanation might be that, whilst day 12 CFU-S were transduced in the original cultures, even more primitive (stem) cells, which would be expected to give rise to the day 12 CFU-S assayed after 5 weeks either were not transduced or alternatively did not express sufficient hATPA/GA. The former of these two possibilities is clearly untrue, since mice from the same cohort of animals as those treated with BCNU exhibited significant resistance of the d12 CFU-S population to two other O 6 -alkylating agents, temozolomide and mitozolomide. 49, 50 However, given the stochiometric, autoinactivating nature of ATase, excess damage in genomic DNA can lead to depletion of the repair capacity of cells and, if sufficient extra repair protein is not synthesised prior to cell division to complete the DNA repair process, cell death will ensue. Chloroethylating agents such as BCNU, form irreversible cross-links in DNA within about 6 h of exposure of cells to drug. 60, 61 Thus one possible explanation might be that the CFU-S express hATPA/GA, but at insufficient levels to effect repair of all of the initial damage caused by BCNU exposure and that fixation of damage leads to death despite further hATPA/GA synthesis. This clearly cannot be the case since, in the absence of O 6 -beG, a protective effect was seen in the day 12 CFU-S which was at least as good as that seen in the GM-CFC and thus the levels of hATPA/GA in the CFU-S population must be adequate to confer a survival advantage following BCNU exposure. Only in the presence of O 6 -beG is the protective effect of hATPA/GA expression in CFU-S lost. This is consistent with inactivation of an O 6 -beG-sensitive (eg wild-type) form of hAT prior to BCNU treatment of the animals. In a previous study, we have examined the effect of pretreatment of normal mice with O 6 -beG on the toxicity of either temozolomide or BCNU against GM-CFC and CFU-S. For temozolomide, the extent of sensitisation of both the GM-CFC and CFU-S populations by O 6 -beG was the same (1.63-and 1.68-fold, respectively). However, when the effect of O 6 -beG pretreatment on BCNU-induced cell loss was assessed, it was noted that the effect on the CFU-S population (8.25-fold sensitisation) was much greater than that on the GM-CFC population (4.57-fold sensitisation). This result seemed consistent with the inactivation of wild-type hAT in the CFU-S population, followed by fixation of BCNU-induced DNA damage prior to resynthesis. In the current studies, however, the mutant form of hAT used has been previously demonstrated to be resistant to inactivation by O 6 -beG and to confer O 6 -beG-insensitive protection against O 6 -alkylating agents to human and murine haemopoietic cells. 48, 49, 52 Furthermore, in this study the GM-CFC compartment of hATPA/GA-transduced mice showed a highly significant protective effect against the combination of BCNU and O 6 -beG. Thus a direct effect of O 6 -beG/BCNU on the hATPA/GA-transduced CFU-S is unlikely. A similar argument also discounts the effects both of other DNA lesions produced by BCNU, or of damage to other cellular components (eg carbomylation of proteins 62 ) either of which may be potentially lethal but not repairable by hAT: any effect on CFU-S in the presence of O 6 -beG, should also be evident in the absence of O 6 -beG. All of the above leads us to the conclusion that the lack of protection of hATPA/GA-transduced CFU-S from BCNU toxicity following pretreatment with O 6 -beG is likely to be a function of inactivation of wild-type hAT in a cell type other than the CFU-S itself. One possible explanation for this effect may lie in the nature of the CFU-S assay, which is not strictly a measure of cell viability, but is a functional measure of the ability of cells to proliferate and differentiate after seeding within the spleens of recipient mice. The bone marrow microenvironment plays a crucial role in regulating haemopoietic cell production. 63 BCNU has been demonstrated to cause quantitative changes in bone marrow stromal matrix components 64 and to impair the capacity of haemopoietic stroma to support haemopoiesis in vitro.
65 Similar effects to those described for BCNU have been seen in vivo following treatment of mice with 239 Pu, 66 ␥-irradiation 67 or busulphan. 68 That is, a defect in stromal function leading to a reduced capacity to support CFU-S survival/proliferation. Thus it may be possible that a detrimental effect of BCNU on the bone marrow microenvironment is exacerbated by pretreatment with O 6 -beG and that this leads to loss of functional CFU-S, either through differentiation or through commitment to apoptosis as a result of insufficient levels of growth/survival factors. The issue as to whether the murine bone marrow microenvironment following transplantation is derived from donor or host is not fully resolved. However, the cumulative data published thus far suggest that the endothelial and fibroblast populations are likely to be of host origin. [69] [70] [71] Moreover, in the mice used in these experiments, reconstitution of the bone marrow was achieved using the non-adherent fraction of cells collected following co-cultivation with retroviral producers. It would seem unlikely, therefore, that many (adherent) fibroblast or endothelial cells were transferred and that this portion of the microenvironment would be host derived. Thus in hATPA/GA-transduced mice, any ATase activity in the (host-derived) fibroblast/endothelial portion of the bone marrow stroma would be wild type and thus susceptible to inactivation by O 6 -beG. As a consequence of this, these components of the bone marrow microenvironment may be sensitised to BCNU and thus loss of hATPA/GA-transduced CFU-S following treatment with the combination of O 6 -beG and BCNU may reflect increased damage to the bone marrow microenvironment and not direct toxicity of BCNU on the CFU-S compartment (although it will clearly be important to investigate this further using appropriate in vitro assays). Similar evidence of host origin of the bone marrow stroma has also been seen in humans following allogeneic transplantation. [72] [73] [74] [75] Given this, it seems unlikely that ex vivo transfer of drug resistance genes to bone marrow will confer full chemoprotection to the bone marrow stroma and it is possible that exacerbated microenvironment damage may also lead to a reduction in stem cell protection in patients undergoing clinical trial.
The above data indicate that the protective effects seen thus far in pre-clinical studies may not be entirely predictive of the ability or otherwise to provide genetic protection of stem cells with ATase, when the active drug is BCNU. If this is the case, and a similar senario applies in humans, then clinical trials of this approach in combination with O 6 -beG/BCNU may show only short-term protective effects, with longer-term toxicities unaffected. This could limit the ability to provide sustained marrow recovery in the face of repeated, dose-intensive chemotherapy. It remains to be seen whether the observations reported here with BCNU also apply to other O 6 -alkylating agents. Certainly our experience with temozolomide is that good protection of the CFU-S compartment from the combination of this agent and O 6 -beG is seen following transfer of the hATPA/GA gene into bone marrow. We have also seen evidence of protection of CFU-S against the toxicity of the cross-linking imidazotriazine, mitozolomide, both in the presence and absence of O 6 -beG. 50 However, there is as yet no evidence of protection of CFU-S from the effects of any chloroethylnitrosourea in combination with O 6 -beG. The BCNUrelated agent, CCNU is currently being used in a clinical trial of ATase-mediated chemoprotection. 76 This study makes use of the wild-type hAT gene, without O 6 -beG and thus effects on primitive cells may not prove problematic. However, since the next logical extension of this trial would be to incorporate a mutant ATase with O 6 -beG sensitisation of tumours, it would seem prudent to investigate whether a protective effect in CFU-S can be demonstrated. These studies are in hand.
